Evidence map›Paper›PMID 42428551›Full record

ArticleMedComm2026

Acylglycerol Kinase Inhibition Restores Mitophagy and Alleviates Alzheimer's Disease Pathology.

Wensheng Li, Xuan Yu, Cuiping Guo, Yuting Huang, Zhen Wei, Yi Liu, Jian-Zhi Wang, Rong Liu, Weike Ji, Qiuhong Duan and 3 more

Abstract read
In one paragraph

Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Wensheng LiDepartment of Biochemistry and Molecular Biology School of Basic Medicine, Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China.
Xuan YuDepartment of Pathophysiology School of Basic Medicine Tongji Medical College Huazhong University of Science and Technology Wuhan China.
Cuiping GuoDepartment of Pathophysiology School of Basic Medicine Tongji Medical College Huazhong University of Science and Technology Wuhan China.
Yuting HuangGI Cancer Research Institute Tongji Hospital, Huazhong University of Science and Technology Wuhan China.
Zhen WeiDepartment of Pathology Maternal and Child Health Hospital of Hubei Province Tongji Medical College, Huazhong University of Science and Technology Wuhan China.
Yi LiuDepartment of Pathophysiology School of Basic Medicine Tongji Medical College Huazhong University of Science and Technology Wuhan China.
Jian-Zhi WangCo-Innovation Center of Neurodegeneration Nantong University Nantong China.
Rong LiuDepartment of Pathophysiology School of Basic Medicine Tongji Medical College Huazhong University of Science and Technology Wuhan China.
Weike JiDepartment of Biochemistry and Molecular Biology School of Basic Medicine, Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China.
Qiuhong DuanDepartment of Biochemistry and Molecular Biology School of Basic Medicine, Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China.
Jing WangDepartment of Immunology School of Basic Medicine Tongji Medical College Huazhong University of Science and Technology Wuhan China.
Guihua WangGI Cancer Research Institute Tongji Hospital, Huazhong University of Science and Technology Wuhan China.
Xiaochuan WangCo-Innovation Center of Neurodegeneration Nantong University Nantong China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitophagy is a conserved cellular process that removes dysfunctional or excess mitochondria. Increasing evidence suggests that impaired mitophagy plays a crucial role in AD development. Promoting mitophagy has been shown to be protective in models of AD, representing an important target of Alzheimer's disease (AD). However, the molecular mechanisms underlying impaired mitophagy in AD are still elusive. Here, we provide evidence that highly expressed acylglycerol kinase (AGK), a mitochondrial lipid kinase associated with mitochondrial protein transport, glycolysis, and platelet formation, is a key mediator of mitophagy in AD. We found that AGK promoted the binding of ATPase family AAA domain containing 3A to translocase of the inner mitochondrial membrane 23 and sequentially increased mitochondrial import of PTEN-induced putative kinase 1, leading to the decrease of mitophagy. Further investigations revealed that the AGK downregulation in neuronal cells and APP/PS1 mice enhanced mitophagy, increased mitochondrial membrane potential, decreased pathological Tau/Aβ and neuroinflammation, and alleviated cognitive dysfunctions in the mice. Altogether our findings indicate that AGK plays a critical role in mediating mitophagy defects in AD; furthermore, downregulation of AGK promotes mitophagy and the decrease of Aβ and pathological Tau, providing an encouraging therapeutic treatment for AD.

Indexed as

acylglycerol kinaseAlzheimer's diseaseATPase family AAA domain containing 3Amitophagytranslocase of the inner mitochondrial membrane 23

Identifiers

PMID42428551
PMCPMC13346768

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.